meningioma contraindacation to peptides radiation - PRRTmeningioma Peptides Meningioma Contraindications to Peptides: Navigating Risks and Treatment Options

EANM guidelines Meningiomas, the most common primary brain tumors in adults, accounting for approximately a third of all intracranial neoplasms, can present complex treatment challenges.(PDF) Joint EANM/EANO/RANO/SNMMI practice guideline ... While surgery and radiotherapy remain primary interventions, systemic medical therapies are increasingly considered for treatment-refractory cases.Early Preventive Strategies and CNS Meningioma Among these emerging treatments, peptide receptor radionuclide therapy (PRRT) has shown promise, particularly for advanced, recurrent, or progressive meningiomas.作者：D Sescu·2023·被引用次数：3—It is well established that exposure to IR significantly increases the risk of developingmeningiomas, with studies quoting an increase of up to 10-fold. However, as with any medical intervention, understanding the contraindications and potential side effects associated with peptides is crucial for patient safety and treatment efficacyPeptideswere designated asmeningioma... The chemotherapy and targeted therapy used to treatmeningiomasalso display low efficacy and manyside effects..

Peptide Receptor Radionuclide Therapy (PRRT) in Meningioma Treatment

PRRT is a targeted therapy that delivers high doses of radiation directly to tumor cellsJoint EANM/EANO/RANO/SNMMI practice guideline .... This approach leverages the expression of somatostatin receptors (SSTRs) on many meningiomas, similar to their presence on neuroendocrine tumors. By using radiolabeled peptides that bind to these receptors, PRRT can effectively deliver therapeutic radiation to the tumor site. Studies have demonstrated that PRRT meningioma treatment can be safe, well-tolerated, and effective in controlling disease progression in patients with meningiomas. For instance, research has indicated that PRRT with 111In-Pentetreotide can be a safe and effective option for disease control. Furthermore, new research presented in The Journal of Nuclear Medicine deems PRRT a safe and efficacious alternative for advanced meningiomas.

Despite the therapeutic potential, certain conditions and patient factors can serve as contraindications to PRRT作者：JZ Wang·2024·被引用次数：100—... risk ofmeningiomadevelopment, relatively few modifiable risk factors have been definitively identified. These few include ionizingradiation.... The Joint EANM/EANO/RANO/SNMMI practice guideline adapts contraindications for PRRT from guidelines for neuroendocrine tumors. While absolute contraindications are not extensively detailed in publicly available summaries, general principles of patient suitability for radiation therapy apply.作者：CK Fodi·2022·被引用次数：15—Studies have shown thatmeningiomasexpress somatostatin receptors. It is well known from treating neuroendocrine tumors thatpeptide... This includes assessing overall health, renal and hepatic function, and the presence of other severe comorbidities that could compromise a patient's ability to tolerate treatment and its associated side effects.2025年7月19日—4.PeptideReceptor Radionuclide Therapy (PRRT) · Investigational treatment for progressivemeningiomas· Consider only if other local therapy ... Comprehensive patient evaluation by a multidisciplinary team is essential to determine eligibility.2024年10月30日—Peptidereceptor radionuclide therapy (PRRT) has been deemed a safe and effective alternative treatment for patients with advancedmeningiomas, according to new research published in The Journal of Nuclear Medicine.

Understanding Potential Contraindications and Side Effects

The investigation into meningioma contraindication to peptides is an ongoing area of research. While PRRT has shown a good safety profile, understanding potential risks is paramount. Some research suggests a potential link between the long-term use of certain progestogen drugs, such as high doses of medroxyprogesterone acetate and cyproterone acetate, and an increased risk of meningioma development.Meningiomasare the most the common primary brain tumors in adults, representing approximately a third of all intracranial neoplasms. A dose-dependent association between cyproterone acetate and the risk of meningioma has been observed, with studies indicating a higher risk even after discontinuation. Similarly, Depo-Provera use has been associated with meningioma risk. While these findings relate to risk factors for developing meningiomas, they underscore the importance of a thorough medical history, including previous or current use of hormonal medications, when considering any treatment involving peptides.

Other factors that may influence treatment decisions, though not strictly considered absolute contraindications for peptides in PRRT, can include:

* Radiation exposure: Certain familial syndromes and prior exposure to ionizing radiation can increase the risk of developing meningiomas. While this is a risk factor for the disease itself, significant prior radiation to the same treatment area might be a consideration for subsequent therapies.2025年8月6日—External beam radiotherapy (EBRT) is the treatment of choice for irresectablemeningioma. Due to the strong expression of somatostatin ...

* Specific Gene Mutations and Familial Syndromes: While research is still evolving, understanding the genetic landscape of meningiomas may reveal specific contraindications in the future.

* Pregnancy and Breastfeeding: As with most radiation therapies, PRRT is contraindicated in pregnant or breastfeeding individuals due to potential harm to the fetus or infant.作者：S Severi·2024·被引用次数：13—Certain familial syndromes and exposure to ionizing radiation can increase the risk of developing meningiomas by 6–10 times (2,3).

The side effects of PRRT can vary but may include fatigue, nausea, myelosuppression (low blood counts), and kidney damage. The use of peptides for meningioma treatment is a complex area that requires careful consideration of individual patient circumstances, potential risks, and the expected benefits of therapy. The development of innovative treatments for meningiomas, including peptide-based therapies, continues to offer hope for patients with challenging diagnoses.Use of high dose cyproterone acetate and risk ... Exploring the latest advancements and consulting with experienced neuro-oncology teams are vital steps in navigating these treatment options and ensuring the best possible outcomes.Joint EANM/EANO/RANO/SNMMI practice guideline ...